Zika virus (ZIKV) outbreak has emerged as a global health threat, particularly in tropical areas, over the past few years. No antiviral therapy or vaccine is available at present.
1
ZIKV is a mosquito-borne virus that causes symptoms such as mild fever, skin rashes, headache, and joint pains. Additionally, recent studies have shown conclusive links between ZIKV and two serious conditions: microcephaly in newborns and neurological disorders such as Guillain-Barré syndrome in adults. 2 Currently there is no antiviral or vaccine available. Because of the threat to public health worldwide, 3 the World Health Organization (WHO) declared a global emergency in February 2016. Thus, there is an urgent need to discover and develop effective anti-ZIKV drugs and vaccines as soon as possible.
To rapidly identify anti-ZIKV drugs to fight the current outbreak, the repurposing of currently existing drugs with potential anti-ZIKV activity may be practical. Such approved drugs already have well documented safety and pharmacokinetic profiles, and might be able to pass through regulatory pathways and be approved for clinical evaluation more rapidly than new compounds. [4] [5] [6] [7] [8] [9] [10] We previously developed cell-based antiviral assays for the screening of compounds against human immunodeficiency virus (HIV) and DENV. 11, 12 In the present study, we have established a cell-based assay in Vero cells for the detection of ZIKV through the quantification of cytopathic effect (CPE)-induced cell death measured by 3-(4,5-dimethylthiazol-2-yl)- 
| Cytotoxicity assay
Cytotoxicity assays were performed as previously described using the MTT assay. Prism 5.0 software as previously described. 12 The selectivity index (SI)
| Antiviral assay
was determined as the ratio of the CC 50 for cell viability to the EC 50 for protection from CPE (SI = CC 50 /EC 50 ).
| Plaque assay
Virus titers were determined by plaque assay in Vero cell cultures as described, 16 with some modifications. Vero cells were seeded in 6-well plate (4 × 10 5 /well). Next day, virus stocks were 10-fold serially diluted and 1 mL of each dilution was added to the monolayers. plates were objectively measured using a plate reader at a wavelength of 570 nm. 19 The 50% effective concentration (EC 50 ), that is, concentration of a compound achieving 50% plaque inhibition, was calculated as above.
| Time-of-addition assay
A time-of-addition (TOA) assay was performed to determine the mode of antiviral activity of the hit compounds for various steps of the ZIKV life cycle. 11, 20 The concentration of the test compounds added were 3-5 times greater than their EC 50 s, as shown in Figure 3 . After 72 h, viral yields in cell culture supernatants were measured by qRT-PCR. 
| Effect of drug pretreatment of host cells on viral infection
This assay was performed to determine whether the employed drugs might target host factors versus various steps in the virus life cycle. 
| Data analysis

| Establishment of a cell-based anti-ZIKV assay
In order to determine the optimal virus infective dose to be used, we first titrated ZIKV in a 96-well plate format by adding virus to Huh 7 or
Vero cells in culture. After 3 days pi, we quantified cell viability in Huh 7
or Vero cells using the MTT assay, and calculated the viral dose that could kill 95% of cells. As shown in Figure 1 , the CCID 95 s in Huh 7 or
Vero cell cultures were 15.84 and 0.18 μL/well, respectively. Since
Vero cells were more susceptible to ZIKV infection and readouts showed less variability, the Vero/MTT assay was employed in subsequent experiments. The signal-to-noise (S/N) ratios and the coefficients of variation (CV) yielded by this Vero/MTT assay were 1.9-fold and 9.8%. A Z′ value of 0.67 was obtained, similar to the result in a recent report on MTT assay. 24 These results indicate that the assay was robust and applicable for the identification of active compounds that might protect against ZIKV-induced cell death.
| Antiviral activity of selected FDA-approved drugs
We initially chose eight compounds (Table 1) Table 1 . PCZ was only effective over a narrow range of concentrations and could not achieve 100% protection at optimal concentrations.
MPA exhibited an EC 50 of 0.32 μM, which is in good agreement with the recently reported EC 50 range of 0.11-1 μM derived from a variety of assays including Vero 76/CellTiter-Glo, 4 HuH-7/flow cytometer, 5 Vero/qRT-PCR, 25 and U2OS/microscopy. 26 The obtained EC 50 value of CQ was also in agreement with values reported by other investigators. 4, 27, 28 The anti-ZIKV activities of the three compounds were confirmed by virus plaque assay as well ( Figure 2B and Table 1 ).
These results indicate that the proposed assay can be used for the screening of anti-ZIKV compounds. Based on the results, we subsequently focused on AQ, an FDA-approved antimalarial drug, for further studies. As shown in Table 1 and Figure 2 , the CC 50 value of AQ exceeded its EC 50 value, suggesting that the inhibition of ZIKV infection was not related to compound-induced cytotoxicity.
| Time-of-addition analysis
To determine the stage of the viral life cycle that the compounds were targeting, we next performed time-of-addition assays. As shown in Figure 3 , the addition of three drugs at their optimal concentration to Vero cells at 0 h pi almost completely inhibited the production of ZIKV. 
| Effect of pretreatment of host cells on viral infection
To better understand the antiviral mechanisms of these agents, drug pretreatment studies were performed to determine whether the drugs The obtained Z‵ factor for the Vero/MTT assay indicates that this assay is robust and amenable for medium-throughput screening purposes, in agreement with a recent report. 24 In addition, the assay is simple and cost-effective compared to recently reported assays, including MTS, plaque, image-based, immunofluorescence, ATP luminescence, and qRT-PCR. 4, 5, 25, 28, 30, 31 Our priority testing of eight compounds has identified four that manifest anti-ZIKV activity. This hit rate is high compared with other Fresh medium was then added with or without drug, following by infection with ZIKV. At 1 h postinfection, the medium was removed and cells were washed three times and the cells were re-incubated with fresh medium in the presence or absence of drug. After incubation for three days, cell viability was measured by MTT assay and the percentages of cell viability relative to the cell control were calculated. Data represent mean ± SD calculated from three independent experiments with duplicate samples repurposing high-throughput screens (HTS) using large compound libraries. [4] [5] [6] 9, 10 This result indicates that knowledge-guided selection of candidate compounds for drug screening could accelerate discovery of new leads. Of note, output from HTS varied with assays employed. 4, 32 As shown in Table 1 , MPA was found to be toxic for Vero cells, that is, above 5 μM in our assay, consistent with a recent report that used an ATP luminescence assay, 4 but not one that used an image-based assay. 5 Ribavirin is a well-known broad spectrum antiviral against several RNA viruses with diverse mechanisms of action. 4 However, ribavirin did not show antiviral activity against ZIKV in our assay, in agreement with a recent report. 4 AQ, one of the 4-aminoquinoline drugs tested, showed an EC 50 of 3.07 μM, similar to its activity against DENV 14 and ZIKV in a recent report. 33 Of interest, AQ, known to be an inhibitor of autophagy, is safe in pregnancy and its activity to block Ebola virus (EBOV) has been demonstrated at clinically relevant doses. A recent review reported that AQ also inhibits the pathogenicity of ZIKV at similar concentrations to those for EBOV. 34 It was recently reported that AQ inhibits host cathepsin B protein, thereby preventing entry of viruses such as EBOV into host cells. 35 It is likely that AQ acts on this host protein to protect host cells from infection by ZIKV. AQ has well known safety and pharmacokinetic profiles in use for the past 60 years. The EC 50
value for inhibition of ZIKV by AQ was at low μM range. It might be possible to achieve an effective anti-ZIKV by orally administered AQ.
Alternatively, AQ might be used in a combination therapeutic strategy with direct acting antivirals such as sofosbuvir. 32, 36, 37 Moreover, further structure-activity studies and newly synthesized AQ analogues might provide more potent agents against ZIKV. 38 Nevertheless, AQ still needs to be tested in animal models and conducted in clinical trials.
CQ, known to be an endocytosis-blocking agent, had an EC 50 value of 4.05 μM, comparable with that in the literature. 28 However, a recent study reported that CQ did not exhibit any anti-ZIKV activity. 4 This discrepancy with our data could be due to the nature of the assay or different cell line that were used. A recent study reported that CQ showed anti-ZIKV activity in human brain organoids and markedly reduced the amount of virus in maternal blood and neural progenitor cells in the fetal brain in Zika-infected pregnant mice. 39 The anti-ZIKV activity of CQ is particularly interesting, since CQ is known to be well tolerated at relatively high doses and has been reported to manifest antiviral activity against several other types of viruses such as EBOV. 7 It was also reported that CQ and its synthetic analogs are beneficial for many dermatological, immunological, rheumatological, and infectious diseases. [40] [41] [42] Artemisinin, a well-known antimalarial, is believed to work via release of highly reactive oxygen-based free radicals to ultimately kill the parasite. Interestingly, little anti-ZIKV activity was observed for artemisinin at the concentrations tested in this report.
These results suggest that these compounds act via different mechanisms, such that AQ and CQ could serve as molecular probes to study the biology of ZIKV replication. 
